sales@jinjingroup.com

  News Introduction

Vinpocetine(CAS 42971-09-5) treatment of acute cerebral infarction

Date : 2016/10/11 10:54:07

The First Hospital of Yulin City, Shanxi Province, researchers published papers to explore vinpocetine(CAS 42971-09-5) combined with Xueshuantong treatment of acute cerebral infarction clinical efficacy and C-reactive protein (CRP) levels. Studies have shown that vinorelbine combined with thrombolytic therapy alone than thrombolytic therapy for acute cerebral infarction, and may reduce CRP levels, neurological deficit score. The article published in 2014 04 issue of "Integrative Cardiology and cerebrovascular disease magazine".

80 cases of acute cerebral infarction within 72h were randomly divided into two groups. Treatment group combined with vinpocetine(CAS 42971-09-5) and Xueshuantong, the control group only thrombosis. The levels of C-reactive protein and neurological deficit score before and after treatment were observed and the curative effect was evaluated.

The treatment group decreased more significantly than the control group (P <0.05); the total effective rate of clinical treatment group was 92.5%, the treatment group was significantly lower than the control group, Was superior to that of the control group (80.0%), the difference was statistically significant (P <0.05).